Drugs.com - New Drug Approvals

FDA Approves Benlysta (belimumab) Autoinjector for Children with Active Lupus Nephritis

Philadelphia, PA June 24 2025 -- GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stimulator (BlyS)-specific inhibiting monoclonal...

Jun 25, 2025 - 00:25
 0
FDA Approves Benlysta (belimumab) Autoinjector for Children with Active Lupus Nephritis
Philadelphia, PA June 24 2025 -- GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stimulator (BlyS)-specific inhibiting monoclonal...
Read More

Tags:

Previous Article

Drug Safety Communication: FDA Investigating Deaths Due to Acute Liver Failure i...

Next Article

Childhood vaccination coverage was falling across the globe even before Covid

Related Posts

FDA Approves Jobevne (bevacizumab-nwgd), a Biosimilar t...

May 12, 2025  0

FDA Approves Vykat XR (diazoxide choline) to Treat Hype...

May 12, 2025  0

U.S. Food and Drug Administration Updates Camzyos (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications

U.S. Food and Drug Administration Updates Camzyos (mava...

May 12, 2025  0